SCHEMBL2192579

SCHEMBL2192579

[2H]C([2H])([2H])c1onc(C(=O)OCC)c1Br

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
MLYCD O95822 1/20 0.42
CACNA1F O60840 4/20 0.42
CACNA1D Q01668 4/20 0.42
CACNA1S Q13698 4/20 0.42
CACNA1C Q13936 4/20 0.42
TARBP2 Q15633 3/20 0.42
HTT P42858 1/20 0.40
ABCB1 P08183 1/20 0.38
KDM4E B2RXH2 1/20 0.37
POLB P06746 1/20 0.37
PKM P14618 1/20 0.37
TDP2 O95551 2/20 0.37
HTR2C P28335 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12416482 0.90 ALDH1A1 (0.48) ALDH1A1MLYCDCACNA1FCACNA1DCACNA1S
SCHEMBL10627069 0.80 TARBP2 (0.42) ALDH1A1MLYCDCACNA1FCACNA1DCACNA1S
SCHEMBL12416429 0.76 ALDH1A1 (0.50) ALDH1A1MLYCDCACNA1FCACNA1DCACNA1S
SCHEMBL436752 0.73 ALDH1A1 (0.48) ALDH1A1MLYCDCACNA1FCACNA1DCACNA1S
SCHEMBL766573 0.73 TARBP2 (0.42) ALDH1A1MLYCDCACNA1FCACNA1DCACNA1S
SCHEMBL5431807 0.73 NPSR1 (0.45) ALDH1A1KDM4EPOLB
SCHEMBL353667 0.72 ALDH1A1 (0.57) ALDH1A1MLYCDCACNA1FCACNA1DCACNA1S
SCHEMBL2733993 0.72 ALDH1A1 (0.57) ALDH1A1MLYCDCACNA1FCACNA1DCACNA1S
SCHEMBL12926059 0.71 ALDH1A1 (0.46) ALDH1A1MLYCDCACNA1FCACNA1DCACNA1S
SCHEMBL32659821 0.71 MLYCD (0.41) ALDH1A1MLYCDTARBP2HTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140024652-A1 SUBSTITUTED TRIAZOLOPHTHALAZINE DERIVATIVES CONCERT PHARMACEUTICALS, INC. (US) 2014-01-23 US disclosed
US-8557815-B2 Substituted triazolophthalazine derivatives CONCERT PHARMACEUTICALS, INC. (US) 2013-10-15 US disclosed
US-20110172235-A1 SUBSTITUTED TRIAZOLOPHTHALAZINE DERIVATIVES CONCERT PHARMACEUTICALS, INC. (US) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172235-A1 SUBSTITUTED TRIAZOLOPHTHALAZINE DERIVATIVES GPR55, HTR5A, GRK5 ALDH1A1 2452/4885MLYCD 4513/4885CACNA1F 817/4885
US-20140024652-A1 SUBSTITUTED TRIAZOLOPHTHALAZINE DERIVATIVES GPR55, HTR5A, GRK5 ALDH1A1 2452/4885MLYCD 4513/4885CACNA1F 817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.